GlassScriptPhysician profile
John D Patsimas
NPI 1649376849
$14,477.13
in general payments reported to CMS, 2019-2025
57 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,081 · 2020: $2,326 · 2021: $1,987 · 2022: $2,685 · 2023: $1,740 · 2024: $1,560 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,398.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,600.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,518.60 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,505.53 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,094.72 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $815.62 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $745.35 | 2019-2025 | Jardiance, Jascayd |
| Pfizer INC. | $592.53 | 2019-2025 | |
| Lilly USA, LLC | $579.64 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $536.72 | 2019-2024 | |
| Esperion Therapeutics, INC. | $516.41 | 2020-2025 | Nexletol |
| Astellas Pharma US INC | $379.62 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $362.45 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $310.82 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $300.46 | 2021-2024 | |
| Allergan, INC. | $291.16 | 2019-2020 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Patsimas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.